Eosinophilic leukocytes have been implicated as primary effector cells in inflammatory and allergic diseases. When activated by cytokines, human eosinophils secrete and produce a variety of proinflammatory or tissue damaging substances. Although well known for their chemoattractant effects, little is known about the precise contribution of the eosinophil-selective chemokines, eotaxin, eotaxin-2, and eotaxin-3 to the effector functions of eosinophils. This forms the central focus of these investigations for which clone 15-HL-60 human eosinophilic cells were used as the in vitro model. Investigation results suggest that all three subtypes of eotaxin directly stimulate eosinophil superoxide anion generation that is inhibited by neutralizing eotaxin antibody or pretreatment of cells with the receptor antibody anti-CCR3. Pretreatment or co-treatment with each of the eotaxins augmented phorbol myristate-induced superoxide generation. Concentration-dependent degranulation of eosinophil peroxidase was noted for all three chemokines, and potentiation of calcium lonophore-induced degranulation was observed with eotaxin pretreatments. Results of interleukin-5 pretreatment studies suggest that the eotaxin chemokines may act cooperatively to enhance effector functions of eosinophils. Collectively, the present studies have advanced knowledge of the eotaxin family of chemokines to include eosinophil priming and modulation of eosinophil activation and secretion effector functions.
HeimanAS, Allen-GipsonD.Cytokines potentiate human eosinophil superoxide generation in the presence of Nw-nitro-l-arginine methyl ester. Int J Immunopharmacol22: 171–181, 2000.
3.
GiembyczMA, LindsayMA. Pharmacology of the eosinophil. Pharmacol Rev51: 213–340, 1999.
4.
GleichGJ, AdolphsonCR. The eosinophil and bronchial asthma: evidence for a critical role in pathophysiology. In: SandersonCJ Ed. Interleukin-5: From Molecule to a Drug Target for Asthma. New York: Marcel Dekker, Vol. 125: pp 1037, 1998.
5.
HondaK, ChiharaJ.Eosinophil activation by eotaxin: eotaxin primes the production of reactive oxygen species from eosinophils. Allergy54: 1262–1269, 1999.
6.
TenscherK, MetznerB, SchopfE, NorgauerJ, CzechW.Recombinant human eotaxin induces oxygen production, Ca++ mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein. Blood88: 3195–3199, 1996.
BjornsdottirUS, CypcarDM. Asthma: an inflammatory mediator soup. Allergy54: 55–61, 1999.
9.
WhiteJR, ImburgiaC, DulE, AppelbaumE, O'donnellK, O'shannesseyDJ, BraunerM, FornwaldJ, AdamouJ, ElshourbagyNA, KaiserK, FoleyJJ, SchmidtDJ, JohansonK, MacpheeC, MooresK, McNultyD, ScottGF, SchleimerRP, and SarauHM. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukocyte Biol62: 667–675, 1997.
10.
ForssmannU, UguccioniM, LoetscherP, DahindenCA, LangenH, ThelenM, BaggioliniM.Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3 and acts like eotaxin in human eosinophil and basophil leukocytes. J Exp Med185: 2171–2176, 1997.
11.
KitauraM, SuzukiN, ImaiT, TakagiS, SuzukiR, NakajimaT, HiraiK, NomiyamaH, YoshieO.Molecular cloning of a novel human CC chemokine (eotaxin-3) that is a functional ligand of CC chemokine receptor-3. J Biol Chem274: 27975–27980, 1999.
12.
WardlawAJ. Molecular basis for selective eosinophil trafficking in asthma. J Allergy Clin Immunol104: 917–926, 1999.
13.
BerkmanN, OhnonaS, ChungF, BreuerR.Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell Mol Biol24: 682–687, 2001.
ElsnerJ, PeteringH, KlutheC, KummigD, SmolarskiR, PonathP, KappA.Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol28: 2152–2158, 1998.
16.
ShahabuddinS, PonathP, SchleimerRP. Migration of eosinophils across endothelial cell monolayers: interactions among 1L-5, endothelial-activating cytokines, and C-C chemokines. J Immunol164: 3847–3854, 2000.
17.
WhiteJR, LeeJM, DedeK, ImburgiaCS, JurewiczAJ, ChanG, FornwaldJA, DhanakD, ChristmannLT, DarcyMG, WiddowsonKL, FoleyJJ, SchmidtDB, and SarauHM. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic peptide-4-induced eosinophil migration. J Biol Chem275: 36626–36621, 2000.
18.
BetrandCP, PonathPD. CCR3 blockade as a new therapy for asthma. Expert Opin Invest Drugs9: 43–52, 2000.
19.
GhaffarM, HamidQ, RenziPM, AllakhverdiZ, MoletS, HoggJC, ShoreSA, LusterAD, LamkhiouedB.Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells. Am J Respir Crit Care Med159: 1933–1942, 1999.
20.
FabianI, LassM, KletterY, GoldeDW. Differentiation and functional activity of human eosinophilic cells from an eosinophil HL-60 subline: response to recombinant hematopoietic growth factors. Blood80: 788–794, 1992.
21.
BachMK, BrashlerJR, SandersME, BienkowskiMJ. Pitfalls in the quantitative estimation of the secretion of granule proteins by eosinophils. J Immunol Methods142: 243–250, 1991.
22.
HorieS, GleichGJ, KitaH.Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol98: 371–381, 1996.
23.
BischoffSC, BrunnerT, DeWeckA, DalhindenCA. Interleukin-5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med172: 1577–1582, 1990.
24.
TiffanyHL, AlkhatibG, CombadiereC, BergerEA, MurphyPM. CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells. J Immunol160: 1385–1392, 1998.
HeathH, QinSX, RaoP, WuJJ, LarosaG, KassamN, PonathPD, MackayCR. Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest99: 178–184, 1997.
27.
ElsnerJ, HochstetterR, KimmigD, KappA.Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol26: 1919–1925, 1996.
28.
TeranM.CCL chemokines and asthma. Immunol Today21: 235–242, 2000.
29.
HondaK, YamadaY, CuiC, SaitoN, KayabaH, LobayashiY, OyamadaH, KamadaY, KuwasakiT, TsurufujiS, and ChiharaJ.Effect of eotaxin on the generation of reactive oxygen species from eosinophil cell line, YY-1. Int Arch Allergy Immunol120:(Suppl 1): 48–50, 1999.
30.
FosterPS, MouldAW, YangM, MackenzieJ, MattesJ, HoganSP, MahalingamS, MckenzieAN, RothenbergME, YoungIG, MatthaeKI, and WebbDC. Elemental signals regulating eosinophil accumulation in the lung. Immunol Rev179: 173–181, 2001.
31.
ZimmermannN, DaughertyBL, StarkJM, RothenbergME. Molecular analysis of CCR-3 events in eosinophilic cells. J Immunol164: 1055–1064, 2000.
32.
El-ShazlyA, MasuyamaK, NakanoK, EuraM, SamejimaY, IshakawaT.Human eotaxin induced eosinophil-derived neurotoxin release from normal human eosinophils. Int Arch Allergy Immunol117:(Suppl 1):55–58, 1998.
33.
Bandeira-MelaC, SugiyamaK, WoodsLJ, WellerPF. Eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils. J Immunol166: 4813–4817, 2001.
